Julian Levell
Morpho (United States)(US)Constellation Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Chromatin Remodeling and Cancer, Protein Degradation and Inhibitors, Cancer Mechanisms and Therapy, Peptidase Inhibition and Analysis, Mechanisms of cancer metastasis
Most-Cited Works
- → Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT)(2012)139 cited
- → Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor(2017)115 cited
- → New hypotheses about the structure–function of proprotein convertase subtilisin/kexin type 9: Analysis of the epidermal growth factor‐like repeat A docking site using WaterMap(2010)78 cited
- → Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor(2020)75 cited
- → Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity(2017)66 cited
- → Practical Applications of Deep Learning To Impute Heterogeneous Drug Discovery Data(2020)58 cited